These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 4647306)
1. [Possibilities of the treatment of chronic liver diseases with and without vitamin B 12 -folic acid administration]. Börner E Med Welt; 1972 Aug; 23(31):1077-80. PubMed ID: 4647306 [No Abstract] [Full Text] [Related]
2. [On the therapy of chronic inflammatory liver diseases without or with vitamin B 12-folic acid]. Burgmann W Munch Med Wochenschr; 1966 Sep; 108(37):1805-8. PubMed ID: 6014771 [No Abstract] [Full Text] [Related]
3. [Clinical experience report on Hepavis]. Menninger U; Menninger W Med Welt; 1980 Oct; 31(42):1519-21. PubMed ID: 7453534 [No Abstract] [Full Text] [Related]
4. [Treatment of chronic liver diseases with vitamin B 12]. Wildhirt E Med Welt; 1965 Jul; 27():1489-92. PubMed ID: 5838530 [No Abstract] [Full Text] [Related]
5. [Clinical observations on the use of an amino-acid and vitamin compound in acute and chronic hepatopathies]. Passerini A; Polito C; Lancia M Minerva Med; 1968 Jul; 59(55):3092-5. PubMed ID: 4233590 [No Abstract] [Full Text] [Related]
6. [Hepagrisevit forte in chronic liver diseases]. Kollatz E; Kramer A; Schopper W; Siede W Med Klin; 1965 Dec; 60(50):2032-5. PubMed ID: 5331151 [No Abstract] [Full Text] [Related]
7. [Clinico-experimental findings on the use of a new liver protective agent]. Catalfamo G; Melotti G; Soffritti E Minerva Med; 1967 Apr; 58(34 Suppl):1605-12. PubMed ID: 4226047 [No Abstract] [Full Text] [Related]
8. [Hepatitis course with and without vitamin B12--folic acid therapy]. Börner E Med Welt; 1970 Jun; 24():1107-12. PubMed ID: 5487690 [No Abstract] [Full Text] [Related]
9. [Clinical investigation of silymarin in chronic liver diseases (author's transl)]. Realini S; Gonvers JJ; Hofstetter JR Schweiz Rundsch Med Prax; 1975 May; 64(19):595-8. PubMed ID: 51497 [No Abstract] [Full Text] [Related]
10. [Therapeutic effect of a preparation of total liver extract, cyanocobalamin and amino acids of the Krebs cycle, in acute and chronic liver diseases]. Pignattari S; Sarti F; Toscano S; Dal Monte PR Minerva Med; 1972 Jul; 63(53):2861-72. PubMed ID: 5049878 [No Abstract] [Full Text] [Related]
11. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Charatcharoenwitthaya P; Levy C; Angulo P; Keach J; Jorgensen R; Lindor KD Liver Int; 2007 Mar; 27(2):220-6. PubMed ID: 17311617 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of patients with chronic liver diseases with a hepatotrophic preparation]. Pagliaro L Minerva Med; 1971 Jul; 62(57):2840-3. PubMed ID: 4105219 [No Abstract] [Full Text] [Related]
13. [Therapeutic progress in chronic liver diseases]. Wildhirt E Dtsch Z Verdau Stoffwechselkr; 1968; 28(2):207-8. PubMed ID: 4894834 [No Abstract] [Full Text] [Related]
14. [Rational therapy of liver diseases in general practice]. Vorberg G ZFA (Stuttgart); 1976 Jan; 52(2):101-4. PubMed ID: 131437 [No Abstract] [Full Text] [Related]
15. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Kaslow JE; Rucker L; Onishi R Arch Intern Med; 1989 Nov; 149(11):2501-3. PubMed ID: 2684076 [TBL] [Abstract][Full Text] [Related]
16. Significance of alterations in iron absorption in patients with portal cirrhosis. Olatunbosun D; Ludwig J; Corbett WE; Simon JB; Valberg LS Gastroenterology; 1970 Aug; 59(2):188-99. PubMed ID: 5448194 [No Abstract] [Full Text] [Related]
17. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Azadibakhsh N; Hosseini RS; Atabak S; Nateghiyan N; Golestan B; Rad AH Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):779-88. PubMed ID: 19736473 [TBL] [Abstract][Full Text] [Related]
18. [Immunosuppressive therapy of chronic aggressive hepatitis and primary biliary cirrhosis]. Lampe K; Hüdepohl M; Schopen RD Med Klin; 1972 Apr; 67(15):527-34. PubMed ID: 5053009 [No Abstract] [Full Text] [Related]
19. Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver. Cordero P; Campion J; Milagro FI; Martínez JA Hepatology; 2011 Jun; 53(6):2151-2. PubMed ID: 21538430 [No Abstract] [Full Text] [Related]
20. [Treatment of fatty liver with essential phospholipids]. Arendt R; Nowotny P; Teichmann W Z Gesamte Inn Med; 1970 Jul; 25(13):587-9. PubMed ID: 5523267 [No Abstract] [Full Text] [Related] [Next] [New Search]